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Abstract
Although there have been substantial developments in the analysis of uncertainty in economic evaluations of health care 
programmes, the development of methods for one-way sensitivity analysis has been notably slower. Conditional incremental 
net benefit was recently proposed as an approach for implementing probabilistic one-way sensitivity analysis for economic 
evaluations comparing two strategies. In this paper, we generalise this approach to economic evaluations that compare three 
or more strategies. We find that ‘conditional net benefit’ may be used to conduct probabilistic one-way sensitivity analysis 
for economic evaluations comparing any number of strategies. We also propose the ‘conditional net benefit frontier’, which 
may be used to identify the most cost-effective of any number of strategies conditional upon the specific value of a parameter 
of interest.
Key Points 
Probabilistic one-way sensitivity analysis for evaluations 
with three or more strategies should be reported using 
conditional net benefit.
The results of the probabilistic one-way sensitivity analy-
sis for each strategy can be reported using conditional 
net benefit curves.
The implications of the probabilistic one-way sensitiv-
ity analysis for the decision can be reported using the 
conditional net benefit frontier.
1 Introduction
The use of economic evaluation to inform decisions about 
which strategies should be reimbursed, and for which patient 
groups, is accepted as standard practice in developed health 
care systems [1]. Decision makers are often interested in 
whether changes in specific parameters in the evidence 
base could change the assessment of whether the strategy 
being considered represents good or poor value for money. 
McCabe et al. [2] describe how the conventional approach to 
addressing this question, deterministic one-way sensitivity 
analysis, provides decision makers with biased results and 
hence harms the quality of decision making. They go on to 
describe the ‘conditional incremental net benefit’ (cINB) 
approach for one-way sensitivity analysis; this approach 
respects non-linearities in cost-effectiveness models and 
correlations between model parameters in order to provide 
less biased results. However, this ‘incremental’ approach is 
limited to analyses that compare only two strategies. Reim-
bursement decisions often consider three or more strategies, 
which limits the utility of the cINB approach in practice. 
McCabe and colleagues indicated that the underlying con-
cepts could be generalised to analyses with more than two 
strategies, in a manner analogous to Barton and colleagues’ 
cost-effectiveness acceptability frontier (CEAF) [3]. In this 
short paper, we describe the specifics of this approach—the 
‘conditional net benefit frontier’ (cNBF)—and illustrate this 
using a previously published economic evaluation [4].
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2  Probabilistic One‑Way Sensitivity Analysis
In principle, reimbursement decisions guided by economic 
evaluations should be based upon the expected net ben-
efit [E(NB)]. If the objective is to maximise population 
health, then the strategy with the highest E(NB) should 
be chosen. However, reimbursement decisions are rarely, 
if ever, made on the basis of E(NB) alone, and decision 
makers will often ask analysts to address ‘what if’ type 
questions with regards to important parameters in the 
analyses, such as effectiveness, safety, and resource utilisa-
tion. Under these circumstances, decision makers are inter-
ested in whether a parameter could take a value that would 
change the most cost-effective strategy. As McCabe et al. 
described, one of the key differences between determinis-
tic one-way sensitivity analysis and probabilistic one-way 
sensitivity analysis (POSA) is that POSA tells the decision 
maker not only whether such a value is possible, but also 
the probability that such a value will be observed [2].
3  Constructing the Conditional Net Benefit 
Frontier
Generating the data required to construct the cNBF is iden-
tical to the processes described for conducting POSA and 
estimating cINB [2]. Having chosen a parameter for which 
POSA is required, a set of values is selected from the distri-
bution for that parameter, covering the full range of possible 
values. For example, these may be centiles or deciles of the 
distribution in question, depending upon the degree of preci-
sion required. The use of centiles would mean that approxi-
mately 100 discrete values are selected for the parameter 
of interest, such that 1% of the total area of the probability 
density function (PDF) lies between each value.
Since it is not possible to cover the entire range of values 
for distributions that are unbounded from either above (e.g. 
the gamma distribution) or below (e.g. the normal distri-
bution), operationalising the intent of complete coverage 
requires a judgement about how close to the upper and lower 
bound values the assessed range should go; the more pre-
cise the level of analysis chosen for the POSA, the closer to 
covering the full range of values it will get. In our analyses, 
we have covered the range between the 1st and 99th centiles, 
but we might instead have chosen to cover the range between 
the 1st and 9th deciles, or the 1st and 999th milles, depend-
ing upon the degree of precision required. If the gradient 
at the chosen anchor values indicates that a change in the 
indicated decision may occur should the selected parameter 
take a value outside the chosen range, analysts may choose 
to extend the POSA range as a form of threshold analysis.
Once the parameter values to be considered are selected, 
for each value, the analyst runs a full probabilistic analysis 
of the model using a Monte Carlo simulation, whilst holding 
the parameter of interest constant at the selected value. For 
each probabilistic analysis, the expected costs and outcomes 
for each strategy are recorded. This process is repeated for 
each of the selected values for the parameter of interest.
The conditional expected cost and outcome data produced 
in the previous step are used to calculate either the condi-
tional expected net health benefit or the conditional expected 
net monetary benefit, for each strategy [5]. The conditional 
expected net monetary benefit is calculated using Eq. 1:
where NMB denotes net monetary benefit, λ denotes 
the value of a unit of benefit [e.g. quality-adjusted life 
years  (QALYs)], H denotes the expected health benefit 
(e.g. QALYs) conditional upon the value of the parameter of 
interest, and C denotes the expected costs conditional upon 
the value of the parameter of interest. Note that the overline 
for each of H and C denotes that each is conditional upon the 
value of the parameter of interest (as opposed to the H and C 
resulting from a conventional probabilistic analysis, which 
are not conditional on any parameter taking a specific value).
The conditional expected net health benefit is calculated 
using Eq. 2:
where NHB denotes net health benefit.
POSA works equally well with net health benefit and net 
monetary benefit. For the remainder of this paper, we refer 
simply to conditional net benefit (cNB).
To illustrate the value to decision makers of the cNBF 
when there are more than two strategies, Fig. 1 plots the 
cINB curves for each strategy using the model from a previ-
ously published economic evaluation [4]. This evaluation 
compared five chemotherapy-sparing tests in breast cancer 
to the conventional practice of providing chemotherapy 
to all patients (‘chemo for all’). Figure 1a plots the cINB 
curves with ‘chemo for all’ as the comparator, whilst Fig. 1b 
plots the cINB curves with ‘Prosigna’ as the comparator. 
Both plots show the incremental net monetary benefit of 
each strategy versus the comparator strategy (vertical axis), 
across the range of centiles of the distribution of the ‘cost of 
chemotherapy’ parameter, with the most cost-effective strat-
egy at any given centile being that with the highest cINB. 
In both plots, the ‘risk of recurrence’ strategy is the most 
cost-effective for all values of the ‘cost of chemotherapy’ 
parameter. However, the values of the incremental net mon-
etary benefit (on the vertical axis) are different in the two 
figures due to the use of different comparator strategies. 
(1)cE(NMB) = E(H) − E(C),
(2)cE(NHB) = E
(
H
)
− E
(
C
)
∕,
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Furthermore, whilst the choice of comparator will not affect 
the rank ordering of the technologies, the contribution of 
each strategy to population health cannot be derived from 
either figure without knowing the absolute net benefit of the 
strategy. This impairs the utility of cINB curves for com-
municating the results of an economic evaluation to decision 
makers.
The solution to this problem is to use absolute net ben-
efit rather than incremental net benefit. The strategy with 
the highest (absolute) net benefit is always the best value 
[6]. The same POSA described above will produce the data 
required to calculate the cNB estimate for each strategy for 
each of the selected values for the parameter of interest. If 
the net benefit for a strategy is not affected by changes in 
the parameter, then the cNB will be the same as the net 
benefit for that strategy. This can be seen in Fig. 2. This 
figure reports the results of a POSA for the parameter 
‘cost of Oncotype DX’. We have chosen this parameter for 
Fig. 1  Conditional incremental net benefit curves: a ‘chemo for all’ as comparator; b and ‘Prosigna’ as comparator
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illustration because there are values for this parameter that 
change which strategy has the highest expected cNB. The 
range for the parameter is $270–$7593. The correspond-
ing range of the cNB for the ‘Oncotype DX’ strategy is 
$146,303–$139,891. This is plotted graphically as the con-
ditional net benefit curve (cNBC). Each cNBC shows how 
sensitive the cNB is to the value of the respective parameter. 
The lower the gradient of the cNBC, the less sensitive the 
cNB is to that parameter. The distance between cNBC for 
each strategy allows the decision maker to read off the mag-
nitude of the difference in cNB between strategies, at any 
given value for the parameter of interest. The point at which 
the cNBCs cross serves the same function as a threshold 
analysis, by identifying the value of the parameter at which 
rank ordering of the strategies change.
In this example, only the cNBC for the ‘Oncotype DX’ 
strategy is affected by changes in this parameter; for all other 
strategies, the cNBCs are horizontal lines across the selected 
range of values, since the cNB for these other strategies is 
unaffected by the ‘cost of Oncotype DX’ parameter.
As Fig. 2 shows, the ‘Oncotype DX’ strategy is expected 
to have the highest cNB until the cost of the Oncotype DX 
test approaches the 60th centile of its distribution. Beyond 
this point, the ‘rate of recurrence’ strategy has the highest 
cNB. It is also worth noting that the historic standard of 
care, ‘chemo for all’, is only better value than Oncotype DX 
guided therapy if the cost of Oncotype DX is in excess of 
the 97th centile value of its distribution.
Figure 2 also shows how plotting the cNBCs allows deci-
sion makers to answer a series of ‘what if’ type questions. 
However, over the range of possible values for the ‘cost 
of Oncotype DX’ parameter, only two strategies offer the 
highest value, conditional upon the specific value taken: 
‘Oncotype DX’ or ‘rate of recurrence’. When the decision 
maker is only interested in how the specific value of the 
parameter affects the ‘best buy’ choice—that is, determi-
nation of the single most cost-effective strategy—we can 
eliminate the data on the strategies that are never the best 
buy. Figure 3 shows the cNBCs for ‘Oncotype DX’ and ‘rate 
of recurrence’, plus the cNBF. The analyst can construct the 
cNBF from the cNBCs. The frontier (the red dashed line in 
Fig. 3) plots the highest cNB amongst all of the strategies for 
the complete range of values considered in the POSA. The 
greater the number of strategies that comprise the cNBF, and 
the greater the degree to which the cNBCs for these strate-
gies diverge, the greater the decision uncertainty attributable 
to the parameter of interest.
4  Discussion
The practical application of one-way sensitivity analysis 
has remained deterministic long after probabilistic analysis 
of the reference case became accepted as best practice. In 
part, this delay may have been due to a misperception that 
expected value of perfect parameter information (EVPPI) 
provides identical information to POSA [7], as well as a 
concern that EVPPI is too computationally intensive to be 
routinely undertaken. However, as McCabe and colleagues 
noted, EVPPI does not address the ‘what if’ questions that 
one-way sensitivity analysis targets [2]. Further, advances in 
computational power and more efficient modelling software 
Fig. 2  Conditional net benefit curves
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[8] have made more intensive simulation modelling strate-
gies feasible with standard computing resources. The vol-
ume of simulations required for effective POSA is also a 
magnitude smaller than that conventionally required for 
EVPPI [9].
Many economic evaluations evaluate more than two strat-
egies, and the cINB is ill suited to these cases. For determin-
istic one-way sensitivity analysis to be completely replaced, 
an extension of the principle of POSA to evaluations com-
paring more than two strategies is therefore required. The 
cNB is the natural generalisation of the cINB, since the 
strategy with the highest cNB is the most cost-effective at 
the specific value of the parameter of interest, irrespective 
of the number of strategies being compared [6]. The cNBF 
also provides a general method for identifying the most cost-
effective strategy for any specific value of the parameter of 
interest, irrespective of the number of strategies being com-
pared. While the cINB may still be used for comparisons of 
two strategies, it confers no advantages over the cNB and 
cNBF in such circumstances; we therefore recommend that 
analysts adopt the practice of considering the cNB and cNBF 
in all cases, including comparisons of two strategies, so as 
to standardise a single methodology across all evaluations.
5  Conclusion
The cNBF is analogous to the CEAF [3] and allows decision 
makers to identify the impact of the value taken by a specific 
parameter on which strategy will provide the best value. With 
POSA, cNB, and cNBF, there is no longer any need to report 
deterministic one-way sensitivity analysis of economic evalu-
ations to health care decision makers.
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